- English
- Chinese
- French
- German
- Portuguese
- Spanish
- Russian
- Japanese
- Korean
- Arabic
- Irish
- Greek
- Turkish
- Italian
- Danish
- Romanian
- Indonesian
- Czech
- Afrikaans
- Swedish
- Polish
- Basque
- Catalan
- Esperanto
- Hindi
- Lao
- Albanian
- Amharic
- Armenian
- Azerbaijani
- Belarusian
- Bengali
- Bosnian
- Bulgarian
- Cebuano
- Chichewa
- Corsican
- Croatian
- Dutch
- Estonian
- Filipino
- Finnish
- Frisian
- Galician
- Georgian
- Gujarati
- Haitian
- Hausa
- Hawaiian
- Hebrew
- Hmong
- Hungarian
- Icelandic
- Igbo
- Javanese
- Kannada
- Kazakh
- Khmer
- Kurdish
- Kyrgyz
- Latin
- Latvian
- Lithuanian
- Luxembou..
- Macedonian
- Malagasy
- Malay
- Malayalam
- Maltese
- Maori
- Marathi
- Mongolian
- Burmese
- Nepali
- Norwegian
- Pashto
- Persian
- Punjabi
- Serbian
- Sesotho
- Sinhala
- Slovak
- Slovenian
- Somali
- Samoan
- Scots Gaelic
- Shona
- Sindhi
- Sundanese
- Swahili
- Tajik
- Tamil
- Telugu
- Thai
- Ukrainian
- Urdu
- Uzbek
- Vietnamese
- Welsh
- Yiddish
- Yoruba
- Zulu
- Kinyarwanda
- Tatar
- Oriya
- Turkmen
- Uyghur
Iindaba
-
Iindaba
Unyango lwe-Inoperable Lung Cancer 2026: I-TIL eNtsha kunye noPhulo oluBispecific
Umxholo I-Paradigm Shift kuNyango oluNgasebenzisekiyo loMhlaza weMiphuphu Ukuqonda i-Tumor-Infiltrating Lymphocyte (TIL) Therapy Bispecific Antibodies: Indlela eNgcono-Embini yokuNxibelela uHlahlelo lwe-Eme...
Unyango lokuRecurrent uMhlaza weLung 2026: Ukuphumelela okutsha kunye nezikhokelo zamva nje
Isiqulatho Ukuqonda Umhlaza Wemiphunga ngo-2026 Izikhokelo zamva nje ze-NCCN zoNyango lweRecurrent Non- Small Cell Lung Cancer Breakthrough ye-Recurrent Lung Cancer Strategies for EGFR-Mutant Recu...
Unyango lwe-Indolent Lung Cancer ngo-2026: IiProtokholi eziNtsha zoKuphila ixesha elide
Umxholo Ukuqonda Umhlaza Wemiphunga Ongasebenziyo ngo-2026 I-Paradigm Shift: Ukusuka kuTyando olukhawulezileyo ukuya kuLungelo oluSebenzayo oluNcincisayo kwiiKhetho zoTyando eziQhubelekayo eziPhumayo ekuJoliswe kuzo...
Inqanaba 2A Unyango lomhlaza wemiphunga ngo-2026: Idatha entsha ye-ELCC kwi-Neo-Adjuvant Therapy
Umxholo wokuqonda iNqanaba le-2A Umhlaza weMiphunga yeSeli engeNcinci ka-2026 i-ELCC Ukuphumelela kwi-Neo-Adjuvant Strategies kuNyango oluJoliswe kwi-Driver-Mutated Stage 2A uMhlaza weLung uHlalutya oluthelekisekayo lwe-Trea...
Inqanaba eliBanzi loNyango lweSeli emiNci yoMhlaza weMiphunga ngo-2026: Iza-bren eNtsha kunye neTarlatamab
Umxholo Ukuzivelela kweNqanaba eliBanzi kwiSigaba esiNcinci soNyango loMhlaza wamaLunga weSeli ye-Iza-bren: I-Paradigm Shift kwi-Bispecific ADC Therapy Tarlatamab kunye nokuPhakamisa kwe-T-Cell Engagers uKhuseleko kunye nokunyamezela kwi...
Unyango lokuRecurrent uMhlaza weLung 2026: Ukuphumelela okutsha kunye nezikhokelo zamva nje
Isiqulatho Ukuqonda Umhlaza Wemiphunga ngo-2026 Izikhokelo zamva nje ze-NCCN zoNyango lweRecurrent Non- Small Cell Lung Cancer Breakthrough ye-Recurrent Lung Cancer Strategies for EGFR-Mutant Recu...
